A detailed history of Arizona State Retirement System transactions in Cassava Sciences Inc stock. As of the latest transaction made, Arizona State Retirement System holds 13,123 shares of SAVA stock, worth $30,839. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,123
Previous 11,495 14.16%
Holding current value
$30,839
Previous $141,000 173.76%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$9.57 - $35.08 $15,579 - $57,110
1,628 Added 14.16%
13,123 $386,000
Q2 2024

Aug 05, 2024

BUY
$12.35 - $26.11 $5,779 - $12,219
468 Added 4.24%
11,495 $141,000
Q1 2024

May 07, 2024

SELL
$18.44 - $26.41 $2,212 - $3,169
-120 Reduced 1.08%
11,027 $223,000
Q4 2023

Jan 24, 2024

SELL
$12.64 - $30.11 $1,845 - $4,396
-146 Reduced 1.29%
11,147 $250,000
Q3 2023

Nov 06, 2023

BUY
$16.64 - $25.32 $2,545 - $3,873
153 Added 1.37%
11,293 $187,000
Q2 2023

Aug 01, 2023

SELL
$21.59 - $27.88 $7,513 - $9,702
-348 Reduced 3.03%
11,140 $273,000
Q1 2023

Apr 27, 2023

BUY
$23.46 - $36.44 $17,336 - $26,929
739 Added 6.88%
11,488 $277,000
Q4 2022

Feb 07, 2023

BUY
$27.82 - $44.16 $11,183 - $17,752
402 Added 3.89%
10,749 $317,000
Q3 2022

Nov 07, 2022

BUY
$16.33 - $51.06 $734 - $2,297
45 Added 0.44%
10,347 $433,000
Q2 2022

Jul 28, 2022

BUY
$17.22 - $38.47 $447 - $1,000
26 Added 0.25%
10,302 $290,000
Q1 2022

May 04, 2022

BUY
$32.6 - $53.05 $1,467 - $2,387
45 Added 0.44%
10,276 $382,000
Q4 2021

Feb 04, 2022

SELL
$36.77 - $90.91 $4,485 - $11,091
-122 Reduced 1.18%
10,231 $447,000
Q3 2021

Nov 12, 2021

BUY
$41.79 - $135.3 $11,408 - $36,936
273 Added 2.71%
10,353 $643,000
Q2 2021

Aug 02, 2021

BUY
$32.15 - $89.72 $324,072 - $904,377
10,080 New
10,080 $861,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $94.2M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Arizona State Retirement System Portfolio

Follow Arizona State Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arizona State Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on Arizona State Retirement System with notifications on news.